[{"address1": "1400 Sierra Point Parkway", "address2": "Building C Suite 200", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 822 5500", "fax": "650 636 9773", "website": "https://www.annexonbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barr\u00e9 syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.", "fullTimeEmployees": 71, "companyOfficers": [{"maxAge": 1, "name": "Mr. Douglas  Love Esq., J.D.", "age": 55, "title": "CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 980122, "exercisedValue": 0, "unexercisedValue": 516039}, {"maxAge": 1, "name": "Dr. Dean R. Artis Ph.D.", "age": 62, "title": "Chief Scientific Officer & Executive VP", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 797380, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ted  Yednock Ph.D.", "age": 65, "title": "Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 697760, "exercisedValue": 0, "unexercisedValue": 119297}, {"maxAge": 1, "name": "Mr. Michael  Overdorf M.B.A.", "age": 52, "title": "Executive VP & Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 580469, "exercisedValue": 0, "unexercisedValue": 13124}, {"maxAge": 1, "name": "Mr. Henk-Andre  Kroon M.D.", "title": "Senior Vice President of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jamie  Dananberg M.D.", "age": 65, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shikhar  Agarwal M.B.A.", "title": "Senior VP & Head of Commercial", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sunil  Mehta Pharm.D.", "title": "Senior VP of Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.26, "open": 5.25, "dayLow": 5.07, "dayHigh": 5.335, "regularMarketPreviousClose": 5.26, "regularMarketOpen": 5.25, "regularMarketDayLow": 5.07, "regularMarketDayHigh": 5.335, "beta": 1.23, "forwardPE": -4.870267, "volume": 958557, "regularMarketVolume": 958557, "averageVolume": 1372941, "averageVolume10days": 1869710, "averageDailyVolume10Day": 1869710, "bid": 5.15, "ask": 5.24, "bidSize": 100, "askSize": 100, "marketCap": 553222848, "fiftyTwoWeekLow": 3.86, "fiftyTwoWeekHigh": 8.4, "fiftyDayAverage": 6.0332, "twoHundredDayAverage": 5.803425, "currency": "USD", "enterpriseValue": 330293568, "floatShares": 68835669, "sharesOutstanding": 106594000, "sharesShort": 7769658, "sharesShortPriorMonth": 8691960, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0735, "heldPercentInsiders": 0.00496, "heldPercentInstitutions": 1.0610399, "shortRatio": 6.77, "shortPercentOfFloat": 0.088, "impliedSharesOutstanding": 106594000, "bookValue": 3.197, "priceToBook": 1.623397, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -115159000, "trailingEps": -1.03, "forwardEps": -1.14, "enterpriseToEbitda": -2.647, "52WeekChange": 0.072314024, "SandP52WeekChange": 0.25891924, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ANNX", "underlyingSymbol": "ANNX", "shortName": "Annexon, Inc.", "longName": "Annexon, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "39e86d0b-392a-371c-9e14-996bb9ee6158", "messageBoardId": "finmb_279883519", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.19, "targetHighPrice": 30.0, "targetLowPrice": 9.0, "targetMeanPrice": 15.16667, "targetMedianPrice": 13.0, "recommendationMean": 1.375, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 368699008, "totalCashPerShare": 3.49, "ebitda": -124791000, "totalDebt": 30203000, "quickRatio": 21.501, "currentRatio": 21.808, "debtToEquity": 8.365, "returnOnAssets": -0.24827999, "returnOnEquity": -0.42198002, "freeCashflow": -60814752, "operatingCashflow": -101744000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]